TY - JOUR AU - Auvin, S. AU - Irwin, J. AU - Abi-Aas, P. AU - Battersby, A. PY - 2018 DA - 2018// TI - The problem of rarity: estimation of prevalence in rare disease JO - Value Health VL - 21 UR - https://doi.org/10.1016/j.jval.2018.03.002 DO - 10.1016/j.jval.2018.03.002 ID - Auvin2018 ER - TY - JOUR AU - Rodriguez-Monguio, R. AU - Spargo, T. AU - Seoane-Vazquez, E. PY - 2017 DA - 2017// TI - Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? JO - Orphanet J Rare Dis VL - 12 UR - https://doi.org/10.1186/s13023-016-0551-7 DO - 10.1186/s13023-016-0551-7 ID - Rodriguez-Monguio2017 ER - TY - JOUR AU - Hughes, D. A. AU - Poletti-Hughes, J. PY - 2016 DA - 2016// TI - Profitability and market value of orphan drug companies: a retrospective, propensity-matched case-control study JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0164681 DO - 10.1371/journal.pone.0164681 ID - Hughes2016 ER - TY - BOOK AU - Pomeranz, K. AU - Siriwardna, K. AU - Davies, F. PY - 2020 DA - 2020// TI - Orphan drug report 2020. Report by EvaluatePharma ID - Pomeranz2020 ER - TY - BOOK AU - Pomeranz, K. PY - 2019 DA - 2019// TI - Orphan drug report 2019. Report by EvaluatePharma ID - Pomeranz2019 ER - TY - JOUR AU - Schuller, Y. AU - Biegstraaten, M. AU - Hollak, C. E. M. AU - Klümpen, H. J. AU - Gispen-de Wied, C. C. AU - Stoyanova-Beninska, V. PY - 2018 DA - 2018// TI - Oncologic orphan drugs approved in the EU - do clinical trial data correspond with real-world effectiveness? JO - Orphanet J Rare Dis VL - 13 UR - https://doi.org/10.1186/s13023-018-0900-9 DO - 10.1186/s13023-018-0900-9 ID - Schuller2018 ER - TY - JOUR AU - Kodra, Y. AU - Weinbach, J. AU - Posada-de-la-Paz, M. AU - Coi, A. AU - Lemonnier, S. L. AU - Enckevort, D. PY - 2018 DA - 2018// TI - Recommendations for improving the quality of rare disease registries JO - Int J Environ Res Public Health VL - 15 UR - https://doi.org/10.3390/ijerph15081644 DO - 10.3390/ijerph15081644 ID - Kodra2018 ER - TY - JOUR AU - Cave, A. AU - Kurz, X. AU - Arlett, P. PY - 2019 DA - 2019// TI - Real-world data for regulatory decision making: challenges and possible solutions for Europe JO - Clin Pharmacol Ther VL - 106 UR - https://doi.org/10.1002/cpt.1426 DO - 10.1002/cpt.1426 ID - Cave2019 ER - TY - STD TI - Marketing authorisation [Internet]. Amsterdam: European Medicines Agency; c1995–2020 [cited 2020 Jan 14]. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation. UR - https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation ID - ref9 ER - TY - JOUR AU - Hollak, C. E. AU - Aerts, J. M. AU - Aymé, S. AU - Manuel, J. PY - 2011 DA - 2011// TI - Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders JO - Orphanet J Rare Dis VL - 6 UR - https://doi.org/10.1186/1750-1172-6-16 DO - 10.1186/1750-1172-6-16 ID - Hollak2011 ER - TY - JOUR AU - Germain, D. P. AU - Elliott, P. M. AU - Falissard, B. AU - Fomin, V. V. AU - Hilz, M. J. AU - Jovanovic, A. PY - 2019 DA - 2019// TI - The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts JO - Mol Genet Metab VL - 19 ID - Germain2019 ER - TY - JOUR AU - Stapleton, M. AU - Hoshina, H. AU - Sawamoto, K. AU - Kubaski, F. AU - Mason, R. W. AU - Mackenzie, W. G. PY - 2019 DA - 2019// TI - Critical review of current MPS guidelines and management JO - Mol Genet Metab VL - 126 UR - https://doi.org/10.1016/j.ymgme.2018.07.001 DO - 10.1016/j.ymgme.2018.07.001 ID - Stapleton2019 ER - TY - STD TI - Download medicine data [internet]. Amsterdam: European Medicines Agency; c1995–2019 [cited 2019 Dec 31]. Available from: https://www.ema.europa.eu/sites/default/files/Medicines_output_european_public_assessment_reports.xlsx. UR - https://www.ema.europa.eu/sites/default/files/Medicines_output_european_public_assessment_reports.xlsx ID - ref13 ER - TY - STD TI - EU PAS Register [internet]. Amsterdam: European Medicines Agency; c1995–2016 [cited 2019 Dec 31 through 2020 Jan 2]. Available from: http://www.encepp.eu/encepp_studies/indexRegister.shtml. UR - http://www.encepp.eu/encepp_studies/indexRegister.shtml ID - ref14 ER - TY - STD TI - Medicines [internet]. Amsterdam: European Medicines Agency; c1995–2020 [cited 2019 Dec 31 through 2020 Jan 2]. Available from: https://www.ema.europa.eu/en/medicines. UR - https://www.ema.europa.eu/en/medicines ID - ref15 ER - TY - JOUR AU - Meikle, P. J. AU - Fietz, M. J. AU - Hopwood, J. J. PY - 2004 DA - 2004// TI - Diagnosis of lysosomal storage disorders: current techniques and future directions JO - Expert Rev Mol Diagn VL - 4 UR - https://doi.org/10.1586/14737159.4.5.677 DO - 10.1586/14737159.4.5.677 ID - Meikle2004 ER - TY - JOUR AU - Beutler, E. PY - 1996 DA - 1996// TI - The cost of treating Gaucher disease JO - Nat Med VL - 2 UR - https://doi.org/10.1038/nm0596-523 DO - 10.1038/nm0596-523 ID - Beutler1996 ER - TY - JOUR AU - McCabe, E. R. B. AU - Fine, B. A. AU - Golbus, M. S. AU - Greenhouse, J. B. AU - McGrath, G. L. AU - New, M. PY - 1996 DA - 1996// TI - Gaucher disease. Current issues in diagnosis and treatment. NIH technology assessment panel on Gaucher disease JO - JAMA. VL - 275 UR - https://doi.org/10.1001/jama.1996.03530310054033 DO - 10.1001/jama.1996.03530310054033 ID - McCabe1996 ER - TY - JOUR AU - Mistry, P. K. AU - Batista, J. L. AU - Andersson, H. C. AU - Balwani, M. AU - Burrow, T. A. AU - Charrow, J. PY - 2017 DA - 2017// TI - Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the international collaborative Gaucher group (ICGG) Gaucher registry JO - Am J Hematol VL - 92 UR - https://doi.org/10.1002/ajh.24801 DO - 10.1002/ajh.24801 ID - Mistry2017 ER - TY - JOUR AU - Belmatoug, N. AU - Rocco, M. AU - Fraga, C. AU - Giraldo, P. AU - Hughes, D. AU - Lukina, E. PY - 2017 DA - 2017// TI - Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe JO - Eur J Intern Med VL - 37 UR - https://doi.org/10.1016/j.ejim.2016.07.011 DO - 10.1016/j.ejim.2016.07.011 ID - Belmatoug2017 ER - TY - JOUR AU - Wasserstein, M. P. AU - Caggana, M. AU - Bailey, S. M. AU - Desnick, R. J. AU - Edelmann, L. AU - Estrella, L. PY - 2019 DA - 2019// TI - The New York pilot newborn screening program for lysosomal storage diseases: report of the first 65,000 infants JO - Genet Med VL - 21 UR - https://doi.org/10.1038/s41436-018-0129-y DO - 10.1038/s41436-018-0129-y ID - Wasserstein2019 ER - TY - JOUR AU - Dib, R. AU - Gomaa, H. AU - Ortiz, A. AU - Politei, J. AU - Kapoor, A. AU - Barreto, F. PY - 2017 DA - 2017// TI - Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies JO - PLoS One VL - 12 ID - Dib2017 ER - TY - JOUR AU - Sirrs, S. AU - Clarke, J. T. R. AU - Bichet, D. G. AU - Casey, R. AU - Lemoine, K. AU - Flowerdew, G. PY - 2010 DA - 2010// TI - Baseline characteristics of patients enrolled in the Canadian Fabry disease initiative JO - Mol Genet Metab VL - 99 UR - https://doi.org/10.1016/j.ymgme.2009.11.001 DO - 10.1016/j.ymgme.2009.11.001 ID - Sirrs2010 ER - TY - JOUR AU - Biegstraaten, M. AU - Arngrímsson, R. AU - Barbey, F. AU - Boks, L. AU - Cecchi, F. AU - Deegan, P. B. PY - 2015 DA - 2015// TI - Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry working group consensus document JO - Orphanet J Rare Dis VL - 10 UR - https://doi.org/10.1186/s13023-015-0253-6 DO - 10.1186/s13023-015-0253-6 ID - Biegstraaten2015 ER - TY - JOUR AU - Burton, B. K. AU - Silliman, N. AU - Marulkar, S. PY - 2017 DA - 2017// TI - Progression of liver disease in children and adults with lysosomal acid lipase deficiency JO - Curr Med Res Opin VL - 33 UR - https://doi.org/10.1080/03007995.2017.1309371 DO - 10.1080/03007995.2017.1309371 ID - Burton2017 ER - TY - JOUR AU - Bellgard, M. I. AU - Napier, K. R. AU - Bittles, A. H. AU - Szer, J. AU - Fletcher, S. AU - Zeps, N. PY - 2018 DA - 2018// TI - Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model JO - Blood Cells Mol Dis VL - 68 UR - https://doi.org/10.1016/j.bcmd.2017.01.013 DO - 10.1016/j.bcmd.2017.01.013 ID - Bellgard2018 ER - TY - JOUR AU - Moynihan, R. AU - Bero, L. AU - Hill, S. AU - Johansson, M. AU - Lexchin, J. AU - MacDonald, H. PY - 2019 DA - 2019// TI - Pathways to independence: towards producing and using trustworthy evidence JO - BMJ VL - 367 UR - https://doi.org/10.1136/bmj.l6576 DO - 10.1136/bmj.l6576 ID - Moynihan2019 ER - TY - JOUR AU - Moseley, J. AU - Vamvakas, S. AU - Berntgen, M. AU - Cave, A. AU - Kurz, X. AU - Arlett, P. PY - 2020 DA - 2020// TI - Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines JO - Br J Clin Pharmacol VL - 86 UR - https://doi.org/10.1111/bcp.14279 DO - 10.1111/bcp.14279 ID - Moseley2020 ER - TY - JOUR AU - Koch, C. AU - Schleeff, J. AU - Techen, F. AU - Wollschläger, D. AU - Schott, G. AU - Kölbel, R. PY - 2020 DA - 2020// TI - Impact of physicians’ participation in non-interventional post-marketing studies on their prescription habits: a retrospective 2-armed cohort study in Germany JO - PLoS Med VL - 17 UR - https://doi.org/10.1371/journal.pmed.1003151 DO - 10.1371/journal.pmed.1003151 ID - Koch2020 ER -